A team of British and American researchers have taken another step forward in the fight against manic depression with the discovery that people suffering from the disorder have a distinct chemical signature in their brains.
The researchers from Imperial College London, the University of Cambridge, and the National Institutes of Mental Health in the US say that the discovery may also indicate how the mood stabilisers used to treat the disorder counteract the changes in the brain that it appears to cause.
Manic depression, also known as bipolar disorder, is a debilitating psychiatric condition characterised by alternating mania and depression, affecting about one in every hundred people worldwide.
Though mood-stabilising drugs lithium and valproic acid are relatively effective when it comes to treating the disorder, doctors have long since wondered why these treatments work are poorly understood.
As part of the study, the team compared postmortem brain tissue samples of people with manic depression with those of age and gender matched controls, taking samples from the dorsolateral prefrontal cortex, which controls the processes involved in higher cognitive functioning.
These samples were then analysed using Nuclear Magnetic Resonance spectroscopy.
The boffins found that people with manic depression had different concentrations of chemicals in dorsolateral prefrontal cortex of the brain than those without.
Using mice, they then checked for the effects of lithium and valproic acid and found that these drugs caused the opposite chemical changes to those seen in the bipolar brain tissue samples.